Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium; Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ. Simrén J, et al. Among authors: leuzy a. Alzheimers Dement. 2021 Jul;17(7):1145-1156. doi: 10.1002/alz.12283. Epub 2021 Jan 25. Alzheimers Dement. 2021. PMID: 33491853 Free PMC article.
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.
Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Blennow K, Neto PR. Benedet AL, et al. Among authors: leuzy a. Alzheimers Dement (Amst). 2019 Sep 27;11:679-689. doi: 10.1016/j.dadm.2019.08.002. eCollection 2019 Dec. Alzheimers Dement (Amst). 2019. PMID: 31673598 Free PMC article.
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allué JA, Teunissen CE, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O. Janelidze S, et al. Among authors: leuzy a. Alzheimers Dement. 2022 Feb;18(2):283-293. doi: 10.1002/alz.12395. Epub 2021 Jun 20. Alzheimers Dement. 2022. PMID: 34151519
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, Klein G, Borroni E, Ossenkoppele R, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Hansson O; Alzheimer's Disease Neuroimaging Initiative. Smith R, et al. Among authors: leuzy a. Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875. Epub 2022 Dec 14. Alzheimers Dement. 2023. PMID: 36516028 Free PMC article.
In vivo Detection of Alzheimer's Disease.
Leuzy A, Heurling K, Ashton NJ, Schöll M, Zimmer ER. Leuzy A, et al. Yale J Biol Med. 2018 Sep 21;91(3):291-300. eCollection 2018 Sep. Yale J Biol Med. 2018. PMID: 30258316 Free PMC article. Review.
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.
Heurling K, Ashton NJ, Leuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M. Heurling K, et al. Among authors: leuzy a. Mol Cell Neurosci. 2019 Jun;97:34-42. doi: 10.1016/j.mcn.2019.02.001. Epub 2019 Feb 20. Mol Cell Neurosci. 2019. PMID: 30796959 Free article. Review.
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suárez-Calvet M, Karikari TK, Schöll M, La Joie R, Rabinovici GD, Höglund K, Ballard C, Hortobágyi T, Svenningsson P, Blennow K, Zetterberg H, Aarsland D. Ashton NJ, et al. Among authors: leuzy a. Nat Rev Neurol. 2020 May;16(5):265-284. doi: 10.1038/s41582-020-0348-0. Epub 2020 Apr 22. Nat Rev Neurol. 2020. PMID: 32322100 Review.
87 results